The potent inhibitory effect of tipepidine on marble-burying behavior in mice

Behavioural Brain Research

Volumn 216, Issue 1, 2011, Pages 308-312

  Honda, Sokichi ^a   Kawaura, Kazuaki ^a   Soeda, Fumio ^a   Shirasaki, Tetsuya ^a   Takahama, Kazuo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Antitussives; G protein coupled inwardly rectifying potassium ion (GIRK) channel; Marble burying behavior; Monoamine; Obsessive compulsive disorder; Tipepidine

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; MILNACIPRAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RACLOPRIDE; SCH23390; SEROTONIN 1A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE; TIPEPIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; LOCOMOTION; MALE; MARBLE BURYING BEHAVIOR TEST; MONOTHERAPY; MOUSE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PSYCHOMETRY; THERAPY EFFECT; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; COMPULSIVE BEHAVIOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MOTOR ACTIVITY; PIPERIDINES;

EID: 78149408956     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.08.010     Document Type: Article

References (61)

1. Arima J., Kubo C., Ishibashi H., Akaike N. alpha2-Adrenoceptor-mediated potassium currents in acutely dissociated rat locus coeruleus neurones. J Physiol 1998, 508(Pt 1):57-66.
2. Bächner D., Kreienkamp H., Weise C., Buck F., Richter D. Identification of melanin concentrating hormone (MCH) as the natural ligand for the orphan somatostatin-like receptor 1 (SLC-1). FEBS Lett 1999, 457:522-524.
3. Bayliss D.A., Li Y.W., Talley E.M. Effects of serotonin on caudal raphe neurons: activation of an inwardly rectifying potassium conductance. J Neurophysiol 1997, 77:1349-1361.
4. Bortolozzi A., Díaz-Mataix L., Toth M., Celada P., Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl) 2007, 191:745-758.
5. Bremner J.D., Krystal J.H., Southwick S.M., Charney D.S. Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse 1996, 23:28-38.
6. Carnwath T., Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend 1998, 50:251-254.
7. da Rocha F.F., Correa H. Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1550-1551.
8. Dell'osso B., Mundo E., Marazziti D., Altamura A.C. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive-compulsive disorder: a case series. J Psychopharmacol 2008, 22:210-213.
9. Dell'Osso B., Nestadt G., Allen A., Hollander E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J Clin Psychiatry 2006, 67:600-610.
10. Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am 2006, 29:553-584. xi.
11. Denys D., Zohar J., Westenberg H.G. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 2004, 65(Suppl. 14):11-17.
12. Egashira N., Harada S., Okuno R., Matsushita M., Nishimura R., Mishima K., et al. Involvement of the sigma1 receptor in inhibiting activity of fluvoxamine on marble-burying behavior: comparison with paroxetine. Eur J Pharmacol 2007, 563:149-154.
13. Egashira N., Okuno R., Harada S., Matsushita M., Mishima K., Iwasaki K., et al. Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol 2008, 586:164-170.
14. Egashira N., Okuno R., Matsushita M., Abe M., Mishima K., Iwasaki K., et al. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms. Eur J Pharmacol 2008, 592:103-108.
15. Fineberg N.A., Gale T.M., Sivakumaran T. A review of antipsychotics in the treatment of obsessive-compulsive disorder. J Psychopharmacol 2006, 20:97-103.
16. Fontenelle L.F., Mendlowicz M.V., Versiani M. The descriptive epidemiology of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:327-337.
17. Gehlert D.R., Rasmussen K., Shaw J., Li X., Ardayfio P., Craft L., et al. Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. J Pharmacol Exp Ther 2009, 329:429-438.
18. Greist J.H., Bandelow B., Hollander E., Marazziti D., Montgomery S.A., Nutt D.J., et al. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr 2003, 8:7-16.
19. Harasawa T., Ago Y., Itoh S., Baba A., Matsuda T. Role of serotonin type 1A receptors in fluvoxamine-induced inhibition of marble-burying behavior in mice. Behav Pharmacol 2006, 17:637-640.
20. Hirano K., Kimura R., Sugimoto Y., Yamada J., Uchida S., Kato Y., et al. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 2005, 144:695-702.
21. Hoehn-Saric R., Merchant A.F., Keyser M.L., Smith V.K. Effects of clonidine on anxiety disorders. Arch Gen Psychiatry 1981, 38:1278-1282.
22. Hollander E., Friedberg J., Wasserman S., Allen A., Birnbaum M., Koran L.M. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2003, 64:546-550.
23. 1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol 1995, 68:65-70.
24. Inoue M., Kawaura K., Ogata Y., Honda S., Shirasaki T., Soeda F., et al. Cloperastine remarkably increased the level of DA compared to the level of 5-HT in the brain. Folia Pharmacol Jpn 2009, 133:33. (in Japanese).
25. Inoue M., Shirasaki T., Soeda F., Takahama K. Effect of cloperastine on 5-HT level in rat prefrontal cortex: an in vivo microdialysis study. J Pharmacol Sci 2008, 106(Suppl. 1):187.
26. Inoue M., Soeda F., Shirasaki T., Takahama K. Cloperastine increases dopamine level in the nucleus accumbens of rats. J Pharmacol Sci 2009, 109(Suppl. 1):276.
27. Jan L.Y., Jan Y.N. Heartfelt crosstalk: desensitization of the GIRK current. Nat Cell Biol 2000, 2:E165-E167.
28. 1A receptor. Eur J Pharmacol 2002, 441:137-140.
29. 2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol 1996, 295:147-154.
30. Kaplan A., Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv 2003, 54:1111-1118.
31. + channel mRNAs are differentially expressed in the adult rat brain. J Neurosci 1996, 16:3559-3570.
32. Kawaura K., Ogata Y., Inoue M., Honda S., Soeda F., Shirasaki T., et al. The centrally acting non-narcotic antitussive tipepidine produces antidepressant-like effect in the forced swimming test in rats. Behav Brain Res 2009, 205:315-318.
33. + (GIRK) channel in Xenopus oocytes. Br J Pharmacol 1996, 119:73-80.
34. Lieberman J.A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004, 18:251-267.
35. 2+ currents in rat anterior pituitary cells. Neuron 1992, 8:455-463.
36. Londei T., Valentini A.M., Leone V.G. Investigative burying by laboratory mice may involve non-functional, compulsive, behaviour. Behav Brain Res 1998, 94:249-254.
37. 1A receptor in mice: implications for obsessive-compulsive disorder. J Pharmacol Sci 2005, 99:154-159.
38. Miwa A., Ui M., Kawai N. G protein is coupled to presynaptic glutamate and GABA receptors in lobster neuromuscular synapse. J Neurophysiol 1990, 63:173-180.
39. Nilsson L.C., Eriksson E., Carlsson M., Söerpalm B. Clonidine for relief of premenstrual syndrome. Lancet 1985, 2:549-550.
40. Njung'e K., Handley S.L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991, 38:63-67.
41. 1 agonist C-APB in mice. Psychopharmacology (Berl) 1999, 145:237-250.
42. 1 receptor binding in the striatum of patients with obsessive-compulsive disorder. J Affect Disord 2009, 114:321-326.
43. Owen J.C., Whitton P.S. Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats. Br J Pharmacol 2005, 145:587-592.
44. Pallanti S., Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:400-412.
45. Perani D., Garibotto V., Gorini A., Moresco R.M., Henin M., Panzacchi A., et al. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. NeuroImage 2008, 42:306-314.
46. Pfaffinger P.J., Martin J.M., Hunter D.D., Nathanson N.M., Hille B. GTP-binding proteins couple cardiac muscarinic receptors to a K channel. Nature 1985, 317:536-538.
47. Rasmussen S.A., Eisen J.L. The epidemiology and clinical features of obsessive-compulsive disorder. Psychiatr Clin North Am 1992, 15:743-758.
48. Redmond D.E., Huang Y.H. Current concepts. II. New evidence for a locus coeruleus-norepinephrine connection with anxiety. Life Sci 1979, 25:2149-2162.
49. Sasson Y., Zohar J., Chopra M., Lustig M., Iancu I., Hendler T. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry 1997, 58(Suppl. 12):7-10.
50. Saugstad J.A., Segerson T.P., Westbrook G.L. Metabotropic glutamate receptors activate G-protein-coupled inwardly rectifying potassium channels in Xenopus oocytes. J Neurosci 1996, 16:5979-5985.
51. Shearman E., Rossi S., Szasz B., Juranyi Z., Fallon S., Pomara N., et al. Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Brain Res Bull 2006, 69:204-213.
52. Shinomiya K., Fujii Y., Sugimoto Y., Azuma N., Tokunaga S., Kitazumi K., et al. Effect of paroxetine on marble-burying behavior in mice. Methods Find Exp Clin Pharmacol 2005, 27:685-687.
53. Spanagel R., Eilbacher B., Wilke R. Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat-a pharmacokinetic microdialysis study. Eur J Pharmacol 1994, 262:21-26.
54. Stahl S.M., Grady M.M., Muntner N. Stahl's essential psychopharmacology: the prescriber's guide. Antipsychotics and mood stabilizers 2009, Cambridge University Press, Cambridge, p. xi, 135 p.
55. Takahama K., Shirasaki T., Soeda F. Central mechanisms III: neuronal mechanisms of action of centrally acting antitussives using electrophysiological and neurochemical study approaches. Handb Exp Pharmacol 2009, 219-240.
56. Takahashi T., Yamashita H., Zhang Y.X., Nakamura S. Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res Bull 1996, 41:363-367.
57. Vulink N.C., Denys D., Westenberg H.G. Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. J Clin Psychiatry 2005, 66:228-230.
58. + channel subunit GIRK4. J Neurosci 2000, 20:5608-5615.
59. Witkin J.M. Animal models of obsessive-compulsive disorder. Curr Protoc Neurosci 2008, [Chapter 9: Unit 9.30].
60. Yan Q.S., Reith M.E., Jobe P.C., Dailey J.W. Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res 1997, 765:149-158.
61. Young R., Batkai S., Dukat M., Glennon R.A. TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) exhibits anxiolytic-like activity in a marble-burying assay in mice. Pharmacol Biochem Behav 2006, 84:62-73.